Biography of Sofia Rivera
MD, PhD, Associate Professor at Paris-Saclay University, Head of the Department of Radiation Oncology at Gustave Roussy
Prof. Sofia Rivera is a radiation oncologist, Associate Professor at Paris-Saclay University, and Head of the Department of Radiation Oncology at Gustave Roussy. Internationally recognized for her expertise in radiation therapy for breast cancer, she is engaged in clinical practice, research, and teaching focused on therapeutic innovation, personalized treatment, and improving patients’ quality of life.
After studying medicine at the University of Burgundy, she earned a DES in Radiation Oncology, a DESC in Oncology with a specialization in medical cancer treatment, and a Doctor of Medicine degree in 2008. She completed her training with a master’s degree and then a Ph.D. in radiobiology at Paris-Saclay University within the Inserm U1030 unit. After completing her clinical residency and serving as a hospital physician at Saint-Louis Hospital (AP-HP), she joined Gustave Roussy in 2013, where she gradually built a leading translational and clinical research program dedicated to breast cancer. Her work has significantly contributed to advancing international standards in breast radiation therapy. In particular, she is the coordinator of the HYPOG-01 Phase III randomized multicenter trial, an academic study led by Unicancer, whose five-year results were published in *The Lancet* in 2026. This trial demonstrated the efficacy and safety of a hypofractionated regimen in the treatment of locally advanced breast cancer and represents a major step toward treatments that are shorter, more comfortable for patients, and more sustainable for healthcare systems. Professor Sofia Rivera is also the originator of the “One-Week Breast Radiation Therapy” concept, which aims to reduce treatment duration from several weeks to just a few days while maintaining oncological efficacy. This approach is part of a broader vision of precision radiation therapy that is more accessible, less burdensome, and has a lower environmental impact. Her research at the Inserm U1355 unit also focuses on identifying biomarkers predictive of side effects, preventing these side effects, applying artificial intelligence to radiation therapy, and developing innovative strategies for combining radiation therapy with systemic treatments. Since 2018, she has chaired Unitrad, the national translational and clinical research group in radiation therapy within the French Federation of Cancer Centers (Unicancer). Under her leadership, Unitrad coordinates numerous national and international collaborative projects in the fields of precision radiation therapy, the prediction of side effects, and the optimization of care pathways. She also leads the radiation therapy research for the national Canto-RT cohort, one of the world’s largest prospective cohorts dedicated to evaluating side effects following breast cancer treatment. Deeply involved in the European Society for Radiotherapy and Oncology (ESTRO), Prof. Sofia Rivera holds several strategic leadership roles. She is Chair of the Breast Cancer Focus Group and a member of the Clinical Committee, the Scientific Council, and the National Societies Committee. She plays a major role in developing European guidelines for breast cancer radiation therapy and actively participates in establishing international consensus that shapes clinical practices in Europe and beyond. At the same time, she is deeply committed to training future healthcare professionals. As a faculty member at Paris-Saclay University and the ESTRO School, she coordinates several university courses and participates in numerous national and international training programs. She also helped create the international educational platform Falcon (Fellowship in Anatomical Contouring Workshops), which is now used worldwide for training in anatomical contouring in radiation therapy. With over 95 international scientific publications and an h-index of 25, Professor Sofia Rivera has published in leading medical journals such as *The Lancet*, *The Lancet Oncology*, *JAMA Oncology*, *Radiotherapy and Oncology*, *European Journal of Cancer*, *International Journal of Radiation Oncology*, Biology, Physics, and CA: A Cancer Journal for Clinicians. Her work helps define international standards for modern radiation therapy and promotes increasingly personalized care for patients with breast cancer.